Valacyclovir in Neonatal Herpes Simplex Virus Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

July 24, 2024

Study Completion Date

July 24, 2024

Conditions
Neonatal Herpes Simplex Infection
Interventions
DRUG

Valacyclovir

Upon completion of standard of care acyclovir for treatment of neonatal HSV disease, valacyclovir oral suspension (per ASHP recipe), 20 mg/kg every 8 hours, to be given for 2 (up to 7) days

Trial Locations (1)

35233-1711

University of Alabama - Children's of Alabama, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER